EyePoint Pharmaceuticals - EYPT Company Short-Term Debt

Graphic logo of EyePoint Pharmaceuticals, Inc. (EYPT)

The financial stability of EyePoint Pharmaceuticals (EYPT) is subject to regulatory norms and the outcomes of new drug trials. At the same time, a steady cash flow is ensured by the demand for sustained-release drug delivery systems. The market dynamics of the securities on GURU.Markets, where the indicator is 0.00, confirm the company's pricing power due to unique retinal therapy implants with inelastic demand.

EYPT (EyePoint Pharmaceuticals Inc) Company Short-Term Debts history from 07/04/2022 to 10/28/2026

EYPT (EyePoint Corp): analytical breakdowns and indicator data

- price and consensus price forecast:
Price Chart EyePoint Pharmaceuticals, Inc.|EYPT - Fair Value Consensus
- market capitalization data:
Market Value EyePoint Pharmaceuticals, Inc.|EYPT - Real Price to Acquire Entire Company
- book capitalization data:
Book Value per Share EyePoint Pharmaceuticals|EYPT - Book Capitalization|Market Cap to Net Assets Ratio eyepointpharma.com|EYPT - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital EyePoint Pharmaceuticals|EYPT - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio EyePoint Pharmaceuticals|EYPT - Company Cumulative Debt|Debts to Book Capitalization EyePoint Pharmaceuticals, Inc.|EYPT - Long-Term Debt|Company Short-Term Debt EyePoint Pharmaceuticals
Analysis of all company metrics:EyePoint Pharmaceuticals, Inc., EYPT
Finished products of eyepointpharma.com

EyePoint Pharmaceuticals (EYPT) operates high-tech production of ophthalmological implants, which requires stable funding for sterile lines. This indicator captures the total liabilities with a maturity of up to one year. By analyzing the volume of short-term debt capital, an investor assesses the risk of cash flow gaps against the efficiency of borrowed funds utilization. This price action reflects the balance between operational liquidity and the cost of debt service. Such metrics are critical for evaluating the stability of biopharmaceutical assets.

Competitor analysis for EyePoint Pharmaceuticals

Company Short-Term Debt Alcon (ALC)|BLCO: Company Short-Term Loans and Borrowings|GKOS (Glaukos Corp.) - Company Short-Term Debt|Apellis Corp (APLS) - Company Current Liabilities|BLTE (Belite Bio Inc) - Company Short-Term Debts|Company Short-Term Debts ocutx.com (OCUL)|Harrow (HROW) - Company Current Liabilities|Company Short-Term Loans and Borrowings Viridian Therapeutics Inc (VRDN)|LENZ: Company Short-Term Debts|OCS - Short-Term Debt|KOD (Kodiak Sciences Inc.) - Company Current Liabilities|ALDX - Short-Term Debt|Company Short-Term Debts KALA|IRD (Opus Genetics) - Short-Term Debt|OKYO: Company Short-Term Debt|Short-Term Debt Volume Adverum|Outlook Therapeutics - Company Short-Term Debts|Short-Term Debt clearsidebio.com CLSD|NBY: Company Current Liabilities|Short-Term Debt Kiora Pharmaceuticals Inc. KPRX|ALIM (Alimera) - Company Short-Term Debts|EYEN: Short-Term Debt|Company Short-Term Debt Guardion Health Science (GHSI)|OCUP (ocuphire.com) - Current Liabilities|Company Short-Term Debt OPT (Opthea)